- Company
- Xospata makes progress for reimb...up for DREC review
- by Eo, Yun-Ho Jun 23, 2023 05:45am
- The reimbursement review for the acute myeloid leukemia treatment Xospata is making way to overcome the existing restriction that limits the reimbursement to 4 cycles. According to industry sources, Xospata (gilteritinib), Astellas Korea’s new drug for patients with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutatio
- Company
- IND of LegoChem Bio's ADC was approved by the FDA
- by Hwang, Jin-joon Jun 23, 2023 05:44am
- LegoChem Bioscience announced on the 22nd that it has received approval from the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial plan (IND) for 'LCB84' targeting various solid cancers such as triple-negative breast cancer and colorectal cancer. It submitted a clinical trial protocol to the FDA in May and obtained plan app
- Company
- Expansion of indications for Forxiga as a treatment for HFrE
- by Jung, Sae-Im Jun 23, 2023 05:43am
- AstraZeneca Korea announced on the 22nd that its SGLT-2 inhibitor Forxiga has additionally obtained indications for HFpEF and HFmrEF from the Ministry of Food and Drug Safety. The indication approved this time is to reduce the risk of death due to cardiovascular disease, hospitalization due to heart failure, and urgent hospital visits due to
- Company
- GO for patent litigation, NO for suspension of execution
- by Kim, Jin-Gu Jun 22, 2023 04:14pm
- Janssen Korea has decided not to file a lawsuit for canceling a drug price cut and a request for suspension of execution following the appeal in a patent dispute. It is interpreted as an intention to avoid controversy over the abuse of the suspension system related to the so-called 'Drug Price Reduction and Refund Act' that recently passed the N
- Company
- Leclaza confirms brain metastasis benefits
- by Hwang, byoung-woo Jun 22, 2023 05:41am
- "I think this is a meaningful study in that the third-generation EGFR TKI treatment, such as Lazertinib, showed data related to brain metastasis, but clearly focused on the intracranial response to confirm the effect." When brain metastasis occurs in non-small cell lung cancer patients using 1st or 2nd generation EGFR TKI agents, most patients'
- Company
- JAKi Civinqo completes pricing negotiations for reimb in KOR
- by Eo, Yun-Ho Jun 22, 2023 05:40am
- The atopic dermatitis treatment ‘Cibinqo’ may be listed for reimbursement in Korea from July. According to industry sources, Pfizer Korea completed the pricing negotiations for its new JAK1 inhibitor drug Cibinqo (abrocitinib) with the National Health Insurance Service. Drugs that pass the Health Insurance Policy Deliberative Committee (
- Company
- Joint development & production of DM Combi with SK Chem & AZ
- by Kim, Jin-Gu Jun 21, 2023 10:06am
- SK Chemicals plans to supply products developed and produced to 12 global countries through AZ. SK Chemicals announced on the 19th that it has produced the first commercial product of a diabetes complex jointly developed with AstraZeneca. SK Chemicals explained that it recently held an event to inspect and celebrate the global joint busin
- Company
- Camzyos, which prevents sudden cardiac death in young people
- by Jung, Sae-Im Jun 21, 2023 05:51am
- Korea BMS Pharmaceuticals (CEO Lee Hye-young) announced on the 20th that it held a domestic approval meeting for Camzyos, a treatment for 'obstructive hypertrophic cardiomyopathy (oHCM)', on the 19th and introduced its clinical value. Obstructive hypertrophic cardiomyopathy is a severe and rare heart disease in which thickened left ventricular m
- Company
- [two thousandth]Toxins accumulated in Soyul's body every day
- by Jung, Sae-Im Jun 21, 2023 05:50am
- Soyul, who turned 5 this year, stopped growing at 80cm and is no longer growing. Her arms and legs are not straight and straight. If you try to forcefully stretch it, you could break a bone. This is because Soyul's bone density is low enough to be found in an elderly person in his 80s. Soyul also has carpal tunnel syndrome, which affects 7
- Company
- ALS drug Teglutik may be prescribed at general hospitals
- by Eo, Yun-Ho Jun 20, 2023 05:35am
- SK Chemical’s Lou Gehrig's disease treatment ‘Teglutik’ can now be prescribed at general hospitals in Korea. According to industry sources, Teglutik (riluzole) passed the drug committees (DCs) of tertiary hospitals including Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, as well as medical institution
